Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
DAWNZERA showed durable efficacy, demonstrating 94% overall mean HAE attack rate reduction at one year in OASISplus open-label ...
Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Ot...
Piper Sandler analyst Allison Bratzel maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price t...
TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $59 ...
Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price targ...
Barclays analyst Gena Wang maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price target from ...
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the p...
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target fr...
Raymond James analyst Gary Nachman reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Strong Buy and raises the price tar...
